Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax + Bendamustine + Rituximab in Relapsed DLBCL
NCT01423539Phase 2Withdrawn
- Sponsor
- Genentech
- Start
- Oct 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of navitoclax in diffuse large B-cell lymphoma (DLBCL), sponsored by Genentech. Planned start Oct 2011; status: withdrawn.
02
Drugs
navitoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01423539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423539.